EGFR and neoplasm: The overactivation of NADPH oxidase, ROS-induced OS resulting from MITO dysfunction, and ectopic expression of antioxidative enzymes play a role in EGFR-mediated tumor progression and drug resistance to EGFR TKIs [205].